Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma
Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma
ZUMA-12: A phase 2 study of axi-cel as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL)
Mosunetuzumab induces deep and durable remissions in 3L R/R follicular lymphoma
Initial treatment options for relapsed/refractory multiple myeloma patients
Latest in advanced endometrial cancer
OncoAlert and ecancer weekly round up for November 29th - December 5th, 2021
Paediatric ALL perspective
OncoAlert and ecancer weekly round up for October 18th - October 23rd, 2021
WCLC 2021: Epidemiology of MET Exon 14 mutations
OncoAlert and ecancer weekly round up for October 11th - October 16, 2021
ESMO 2021: Latest in EGFR mutated advanced NSCLC
First-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and brain metastases: Results From CheckMate 9LA